U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. Reports, Manuals, & Forms
  4. Reports
  5. Economic Impact Analyses of FDA Regulations
  6. Medication Guides: Patient Medication Information (Proposed Rule) Preliminary Regulatory Impact Analysis
  1. Economic Impact Analyses of FDA Regulations

Medication Guides: Patient Medication Information (Proposed Rule) Preliminary Regulatory Impact Analysis

The Food and Drug Administration (FDA, the Agency, or we) is proposing to amend its human prescription drug product labeling regulations for Medication Guides (FDA-approved written prescription drug product information distributed to patients). This action, if finalized, will require applicants to create a new type of Medication Guide, referred to as Patient Medication Information (PMI), for prescription drug products, including biological products, used, dispensed, or administered on an outpatient basis and for blood and blood components transfused in an outpatient setting. PMI would be a one-page document with standardized format and content that would be submitted to FDA for approval. This proposed rule is intended to improve public health by providing patients with clear, concise, accessible, and useful written prescription drug product information delivered in a consistent and easily understood format to help patients use their prescription drug products safely and effectively.

Regulatory Impact Analysis

Medication Guides: Patient Medication Information (Proposed Rule) Preliminary Regulatory Impact Analysis (PDF- 444KB)

Federal Register:  88 FR 35694

Publication Date: May 31, 2023

Docket: FDA-2019-N-5959

Back to Top